Dosage guide · 10 mg vial

Thymosin Alpha-1 Dosage Protocol

Thymalfasin · 28-amino-acid immunomodulatory peptide

The reference protocol uses 300 mcg once daily in week 1, then 500 mcg once daily from week 2. With 3 mL of bacteriostatic water, a 10 mg vial is 3.33 mg/mL, so the 300 mcg starting amount is 9 units on a U-100 syringe. The 500 mcg amount is 15 units.

How oftenOnce daily

Starting dose300 mcg

Start = units9 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Thymosin Alpha-1 10 mg vial

View on Peak Peptides

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About Thymosin Alpha-1 References

01 · DOSAGE CHART

Thymosin Alpha-1 dosage chart

Gradual daily approach · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the reference protocol and Peak guide mix, giving 3.33 mg/mL and 30 units = 1 mg.

Thymosin Alpha-1 dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units	Syringe fill
Week 1Start	300 mcg	9 units0.09 mL
Week 2 onwardsMaintenance	500 mcg	15 units0.15 mL

Once daily · any consistent time · subcutaneous injection

The attributed reference protocol increases from 300 mcg to 500 mcg after the first week.

Its supplies calculator uses 8, 12 and 16-week daily protocol lengths.

Reference-site educational amounts — Thymosin Alpha-1 has no TGA-approved Australian dose for this research vial. Education only, not medical advice. Dose amounts adapted from Thymosin Alpha-1 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

3Thymosin Alpha-1 10 mg vials26.6 mg needed in total

591 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle9 mL used for mixing

118Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Thymosin Alpha-1 10 mg vialPeak Peptides Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.090 mL

Equivalent U-100 volume scale position

9markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Thymosin Alpha-1

Protocol overview

Starting dose: 300 mcg once daily in week 1
How it increases: 500 mcg once daily from week 2
Frequency: Once daily
Route: Subcutaneous
Reference length: 8–16 weeks
Common mix: 3 mL BAC water → 3.33 mg/mL

Storage

Before mixing: Keep the sealed freeze-dried vial at 2–8 °C, protected from light.
After mixing: Keep upright at 2–8 °C, away from light; Peak's handling guide uses about 4 weeks after preparation.
Never: Do not freeze a mixed vial or use it if it is cloudy, discoloured or has particles.

How it works

Thymosin Alpha-1, also called thymalfasin, is a synthetic 28-amino-acid peptide. It is studied as an immunomodulator rather than as an antimicrobial drug.

FDA briefing material describes immune effects mediated in part through Toll-like receptor 9 on dendritic and lymphoid progenitor cells. Animal research has reported changes in immune responses, but those findings do not establish a benefit from this research vial.

Illustrated mechanism explainer

What the research shows

A review of four chronic hepatitis B clinical trials covering 195 people reported HBV DNA clearance of 40.6% after 6 months and 25.6% after 12 months in one randomised trial, versus 9.4% in untreated controls; the review says results across hepatitis studies were mixed.
In the 2025 TESTS sepsis trial, 1,106 adults were enrolled and 1,089 were analysed. Twenty-eight-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.97, 95% CI 0.76–1.24).
In TESTS, the treatment was a subcutaneous injection every 12 hours for up to 7 days; no measured safety outcome differed statistically significantly between groups.
FDA states it has approved no drug products containing thymosin alpha-1. The TGA ARTG is Australia’s public database for goods approved for supply; this Peak item is sold as a research sample, not as an ARTG-listed medicine.

Reported side effects

FDA’s review says the most commonly reported reactions in clinical studies were local irritation, redness and injection-site discomfort.
FDA notes reported alanine aminotransferase flares in chronic hepatitis B studies and thyroid-stimulating-hormone abnormalities in chronic hepatitis C studies.
FDA identifies potential immunogenicity concerns for injectable preparations because of aggregation and peptide-related impurities; these risks may differ by formulation and quality controls.
In the 1,089-person TESTS analysis, no safety outcome differed statistically significantly between the thymosin alpha-1 and placebo groups, but that finding applies to the studied medicine and setting.

Important notes

This 10 mg Peak product is a research sample, not a TGA-approved Australian medicine; US FDA has approved no drug products containing thymosin alpha-1.
The 2026 WADA Prohibited List names Thymosin-beta4 and TB-500, not Thymosin Alpha-1 or thymalfasin. Athletes should check the current list and their sport’s rules before using any peptide.
Clinical findings from finished thymalfasin medicines do not establish the identity, quality, dose or effects of an online research vial.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS